Valeant Pharma revenue rises 34 pct

Thu Jul 23, 2015 6:12am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 23 (Reuters) - Drugmaker Valeant Pharmaceuticals International Inc reported a 34 percent rise in quarterly revenue, helped by strength in its dermatology business in the United States.

Net loss attributable to the company was $53 million, or 15 cents per share, in the second quarter ended June 30, compared with net profit of $125.8 million, or 37 cents per share, a year earlier.

Cash earnings, or profit adjusted for one-time items, was $2.56 per share.

Revenue rose to $2.73 billion from $2.04 billion. (Reporting by Ankur Banerjee and Narottam Medhora in Bengaluru; Editing by Don Sebastian)